zanamivir (relenza) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Zanamivir, an antiviral agent, is a neuraminidase inhibitor indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years and older who have been symptomatic for no more than 2 days. Zanamivir has also been shown to significantly inhibit the human sialidases NEU3 and NEU2 in the micromolar range (Ki 3.7 +/-0.48 and 12.9+/-0.07 uM, respectively), which could account for some of the rare side effects of zanamivir. The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.   NCATS

Chemistry

  • SMILES: CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
  • InChIKey: ARAIBEBZBOPLMB-UFGQHTETSA-N
  • Mol. Mass: 332.3098
  • ALogP: -3.58
  • ChEMBL Molecule:
    zanamivir  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$8.6700 - $11.5060
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(2r,3r,4s)-3-(acetylamino)-4-carbamimidamido-2-[(1r,2r)-1,2,3-trihydroxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic acid | 4-guanidino-2,4-dideoxy-2,3-dehydro-n-acetylneuraminic acid | 4-guanidino-neu5ac2en | 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-d-glycero-d-galacto-non-2-enonic acid | 5-(acetylamino)-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-d-glycero-d-galacto-non-2-enonic acid | gana | gg167 | gna | gr-121167 | gr-121167x | modified sialic acid | relenza | zanamavir | zanamivir | zanamivir hydrate | zmr

Organizations (23)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Influenza, Human

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Arthralgia (Phase 2)

Dengue (Early Phase 1)

Diabetes Mellitus, Type 2 (Phase 2)

Healthy Volunteers (Phase 1)

Influenza A virus (Phase 3)

Influenza A Virus, H1N1 Subtype (Phase 1)

Influenza B virus (Phase 3)

Influenza, Human ()

Respiratory Tract Infections (Phase 3)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue